Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Blocking RON Shuts Down Breast Cancer Metastasis

By BiotechDaily International staff writers
Posted on 16 Jan 2014
A recent paper suggested that initiation of breast cancer metastasis did not depend on a specific genetic mutation but rather on improper regulation of molecular pathways that control activation and inactivation of certain critical genes.

Investigators at the University of Utah (Salt Lake City, USA) focused their research on the protein product of the RON gene, known as macrophage stimulating 1-receptor (MST1R), a member of the Met family of receptor tyrosine kinases. The biological activity of RON was mediated by binding of its extracellular ligand, macrophage-stimulating protein (MSP), and the protein macrophage stimulating 1 (MST1). Binding of MSP activated RON and led to cellular growth, motility, and invasion. Recent studies have documented RON overexpression in a variety of human cancers including those of the breast, colon, liver, pancreas, and bladder, which often correlate with poor outcome. Moreover, clinical studies have shown that RON overexpression is associated with metastasis and worse patient outcomes.

In the current study, published in the January 2, 2014, online edition of the journal Cell Reports, the investigators showed that the RON/MSP pathway enhanced metastasis of breast cancer xenografts by reprogramming DNA methylation at specific target genes.

RON/MSP-initiated differential-DNA methylation was found to be the result of upregulation of the enzyme MBD4 (methyl-CpG binding domain protein 4), a thymine DNA glycosylase. MBD4 bound specifically to methylated DNA via an MBD domain at the N-terminus that functioned both in binding to methylated DNA and in protein interactions and a C-terminal mismatch-specific glycosylase domain that was involved in DNA repair.

Knockdown of MBD4 in RON/MSP-expressing breast cancer cells or inhibition of the glycosylase catalytic residue of MBD4 reversed the DNA methylation pattern on specific loci and blocked metastasis.

“Genetic mutations do not drive this mechanism,” said senior author Dr. Alana Welm, associate professor of oncological sciences at the University of Utah. “Instead, it is improper regulation of when genes turn on and off. No one has ever described a specific pathway driving this kind of reprogramming in metastasis, much less a way to therapeutically block it. Also, RON has not previously been known to be involved in reprogramming gene expression.”

“If there is an entire program in the tumor cell that is important for metastasis, blocking one small part of that program, for example, the action of a single gene will probably not be an effective strategy,” said Dr. Welm. “But if you could find a way to turn off the entire program, you are more likely to have the desired effect. We found that inhibiting RON turns off the entire metastasis program in these tumor cells.

Related Links:

University of Utah



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.